Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Director Anna U. Loengard of Clover Health Investments Corp (NASDAQ:CLOV) purchased a total of $68,755 worth of Class A Common Stock on August 13, 2025. The purchases were executed at prices ranging from $2.59 to $2.60, near the current trading price of $2.58. This insider buying comes as the stock has surged 18.5% in the past week, with InvestingPro analysis showing the stock is currently fairly valued.
According to a Form 4 filing with the Securities and Exchange Commission, Loengard acquired 12,000 shares at $2.60 and 14,500 shares at $2.59. These shares are held in custodial IRAs for the benefit of Loengard’s son and daughter, respectively, for which Loengard serves as custodian. Following these transactions, the number of shares owned following the transaction is 27,600 and 29,610 respectively. This purchase aligns with broader management confidence, as InvestingPro data reveals active share buybacks and analyst targets ranging from $2.50 to $5.00.
Loengard also directly owns 448,091 shares of Clover Health Investments. The reporting person no longer has a reportable beneficial interest in 151,725 shares held by her now ex-spouse. Get deeper insights into CLOV’s insider trading patterns and 7 additional key investment tips with InvestingPro’s comprehensive research report.
In other recent news, Clover Health Investments Corp reported its second-quarter 2025 earnings, revealing a revenue of $477.62 million. This figure surpassed the forecasted $468.3 million, marking a 1.99% surprise. Despite the revenue beat, the company’s stock saw a slight dip post-announcement. The stock fell by 1.04% to $2.88 by market close, before seeing a minor increase in after-hours trading. These recent developments highlight the company’s ability to exceed revenue expectations. However, the stock movement indicates investor reactions were mixed.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.